Epigenetics Market Size, Trends, Shares, and Forecast - 2031

The epigenetics market is expected to grow from US$ 1509.99 million in 2022 to US$ 3092.48 million by 2031; it is expected to grow at a CAGR of 14.91% from 2022 to 2031.

A single or multiple changes in phenotype without changing the genotype which affects the cells. The changes occurred due to epigenetics are regular and natural and can also be influenced by several factors such as age, environment, lifestyle, and conditions of diseases. The modifications caused due to epigenetics can be noticeable commonly in the same way cells critically differentiate to end up as skin cells, liver cells, and brain cells. The epigenetic changes can also be resulted into diseases like cancer.

The epigenetics market is segmented on the basis of product, technology, application, end user, and geography. By geography, the market is broadly segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. The report offers insights and in-depth analysis of the market, emphasizing parameters such as market trends, technological advancements, and market dynamics, along with the analysis of the competitive landscape of the leading market players.

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Get FREE CUSTOMIZATION

Epigenetics Market: Strategic Insights

• Get Top Key Market Trends of this report.
  This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Free Sample PDF

Market Insights

Declining Prices of Sequencing Drives Epigenetics Market Growth

The declining costs associated with sequencing strategies and methods influence the scale and scope of genomic research projects. The costs of DNA sequencing performed at the sequencing centers, which is funded by the Institutes, have been tracked by the National Human Genome Research Institute (NHGRI) for many years. This information has served as a key standard for establishing the DNA sequencing capacity and considering improvements in DNA sequencing technologies of the NHGRI Genome Sequencing Program (GSP).

In recent years, next-generation sequencing prices have declined substantially. The cost of first whole human genome sequencing was over US$3.7 billion in 2000, and the sequencing took 13 years for the completion. The sequencing costs reduced to US$1,000 in recent years, and the process requires less number of days. In 2000, cost for sequencing was US$ 3.7 billion, which dropped down to US$ 10 million in 2006 and declined to US$ 5,000 in 2012. Major market players such as Illumina and Roche have introduced breakthrough technologies that have enabled in the cost and time reduction in the sequencing.

Advances in the field of genomics and developments in different methods and strategies for sequencing drop the cost of sequencing, that upsurge the growth of the market.

Increasing Prevalence of Cancer Bolsters Epigenetic Market Growth

Study of epigenetic alterations in cancer, such as aberrant methylation and altered transcription factor binding, provides insights into tumorigenic pathways, which are located above the genetic code. The microarray and next-generation sequencing (NGS) technologies help detect altered methylation patterns and other epigenetic changes in cancer. Illumina works with cancer epigenetics experts to ensure its array and NGS solutions meet the rapidly growing needs of the field.

Cancer cases have been increasing tremendously in recent years, and the trend is anticipated to remain same in the coming years. Lifestyle changes have resulted in exposure to oncogenic factors. The American Cancer Society estimated 1,658,370 cancer cases to be detected in the US in 2015. Cancer can be cured if diagnosed and treated at an initial stage. Cancer sequencing using next-generation sequencing NGS methods provides more information. Additionally, epigenetics aids in cancer research, diagnostics, and treatment.

Thus, the increase in the number of cancer cases is expected to propel the epigenetics market growth in the coming years.

Product Insights

Based on product, the global epigenetics market is segmented into kits, reagents, enzymes, instruments & consumables, and bioinformatics tools. In 2017, the kits segment accounted for the highest market share, and it is expected to register a CAGR of 14.3% during the forecast period. Several kits are available in the market for gene expression analysis, MicroRNA analysis, SNP genotyping analysis, and other procedures. The easy-to-use kits are developed for the epigenetic processes to study DNA methylation and histone modifications (deacetylation and acetylation). Mostly, reagents are included in the kit, and each kit contains a detailed procedure that provides sensitive results rapidly. The epigenetic kits allow researchers to perform experiments and analyze epigenetic modifications efficiently and reliably by using antibodies directed against epitope tags or RNA-binding proteins. In epigenetics, highly efficient and fast processing kits are developed to perform the experiments. So, novel toolkits are developed by various companies. For instance, Merck KGaA offered several toolkits, including chromatin immunoprecipitation (ChIP) Kits, bisulfite DNA modification kits, RNA immunoprecipitation (RIP) Kits, for histone modification, DNA methylation, and RNA regulation. The quality control kits are efficient and fast for the preparation of the epigenetic procedures, which drives the growth of the epigenetics market in the kits segment. 

End User Insights

Based on end user, the global epigenetics market is segmented into academic & research institutes, biotechnology & pharmaceutical companies, and contract research organization. The market is dominated by the pharmaceutical & biotechnology companies segment. The market in the same segment is expected to grow significantly from 2022 to 2031. The growth of the biotechnological products market and various related markets has resulted into massive market consolidations between biotechnology and pharmaceutical companies for enhanced and better treatment options. The growing investments made by companies fueled the market growth in the pharmaceutical & biotechnology companies segment. In March 2017, Thermo Fisher Scientific acquired Core Informatics, a provider of leading cloud-based scientific data platforms. In January 2021, Abcam acquired AxioMx, Inc. to increase the supply of high-quality products generated from innovation. The technological development in molecular biology increased the sequencing procedures. Among the market leaders, the companies have manufactured and designed technologically-advanced epigenetics technology in the last few years. Advanced systems that dominate the market comprise Roche GS FLX (454) and Illumina HiSeq 2000 (Solexa). Various collaborations, investments made by the companies, and technological advancements bolstered the epigenetics market growth in the pharmaceutical & biotechnology companies segment.

Product launches and mergers and acquisitions are among the highly-adopted strategies by the players operating in the global epigenetics market. A few of the recent key product developments are listed below:

• In February 2016, Bio-Rad Laboratories Inc received CE IVD marking for its QX200 Droplet Digital PCR (ddPCR) System, the first digital PCR system with the CE IVD mark to use as an in-vitro diagnostic (IVD) in the European Union.
• In January 2021, Abcam Plc entered an agreement with Roche to obtain exclusive rights to the product portfolio of Spring Bioscience Corporation in the research use only (RUO) field of use, comprising ~760 unique products. 

Epigenetics – Market Segmentation

Based on product, the epigenetics market is segmented into reagents, kits, enzymes, instruments & consumables, and bioinformatics tools. Based on technology, the market is segmented into histone modification, DNA methylation, and others. Based on application, the epigenetics market is segmented into oncology, cardiovascular diseases, and others. Based on end users, the market is segmented into academic & research institutes, biotechnology & pharmaceutical companies, and contract research organization. By geography, the epigenetics market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America)

Company Profiles

• Merck KgaA
• Thermo Fisher Scientific Inc
• Abcam Plc
• Agilent Technologies Inc
• Qiagen
• Bio-Rad Laboratories Inc
• Active Motif
• Perkin Elmer Inc
• New England Biolabs
• Illumina Inc

Epigenetics Market Regional Insights

The regional trends and factors influencing the Epigenetics Market throughout the forecast period have been thoroughly explained by the analysts at The Insight Partners. This section also discusses Epigenetics Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Epigenetics Market Report Scope

Epigenetics Market Players Density: Understanding Its Impact on Business Dynamics

The Epigenetics Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.

Major Companies operating in the Epigenetics Market are:

1. Merck KGaA
2. Thermo Fisher Scientific, Inc.
3. Abcam plc
4. Agilent Technologies
5. Active Motif

Disclaimer: The companies listed above are not ranked in any particular order.